Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL

Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL

Treatment with the peroxisome proliferator-activated receptor γ agonist rosiglitazone has been reported to increase HDL-cholesterol (HDL-C) levels, although the mechanism responsible for this is unknown. We sought to determine the effect of rosiglitazone on HDL apolipoprotein A-I (apoA-I) and apoA-I...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: John S. Millar, Katsunori Ikewaki, LeAnne T. Bloedon, Megan L. Wolfe, Philippe O. Szapary, Daniel J. Rader
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: Elsevier 2011-01-01
Seri Bilgileri:Journal of Lipid Research
Konular:
apolipoprotein A-I
stable isotope
thiazolidinedione
lipoprotein kinetics
high density lipoprotein
Online Erişim:http://www.sciencedirect.com/science/article/pii/S0022227520405048

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520405048

Benzer Materyaller